

2025 ASCO Gastrointestinal Cancers Symposium News Planning Team

All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family

Name	Employment	Leadership	Stock and Other Ownership Interests	Honoraria	Consulting or Advisory Role	Speakers' Bureau	Research Funding	Patents, Royalties, Other Intellectual Property	Expert Testimony	Travel, Accommodations, Expenses	Other Relationship	(OPTIONAL) Uncompensated Relationships	(OPTIONAL) Open Payments Link
Julie R. Gralow													
Pamela L. Kunz					BMS Foundation Medicine		Novartis (Advanced Accelerator Applications) (Inst) RayzeBio (Inst)						
Steven Z. Merlin			AstraZeneca Becton Johnson & Johnson/Janssen Merck pharmaceutical ORGANON & CO Pfizer RAPHAEL PHARMACEUTICAL VIATRIS	MASCC/ Pharmanovia									
Jennifer F. Tseng					Aegerion (I) Amgen (I) AstraZeneca (I) Bristol-Myers Squibb (I) Cubist (I) Curadel Surgical Innovations Daiichi Sankyo/Lilly (I) GlaxoSmithKline (I) Intarcia Therapeutics (I) Merck (I) MyoKardia (I) PanTher Therapeutics Pfizer (I) Quest Diagnostics (I) Sanofi (I) Vertex (I) Zeus (I)								
Laura Vater	Indiana University Health										GoodRx MDLinx		